Project Details
Description
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
| Status | Active |
|---|---|
| Effective start/end date | 10/31/23 → 7/31/27 |
Funding
- HANSA BIOPHARMA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.